BIBLIOGRAPHY
Original Articles
1. Stoner G, Harris C, Bostwick DG, Jones R, Trump BF, Kingbury E, Fineman E, Newkirk C. Isolation and Characterization of Epithelial Cells from Bovine Pancreatic Duct. In Vitro 1978; 14:581-590.
2. Katoh Y, Stoner GD, Bostwick DG, Lavappa KS, Myers GA, Fineman E, Valerio M. Morphological, Growth, and Chromosomal Changes in Bovine Pancreatic Duct Epithelial Cells Exposed to N-Methyl-N-Nitrosoguanidine. In Vitro 1979; 16:791-796.
3. Bostwick DG. Amphetamine Induced Cerebral Vasculitis. Human Pathol 1981; 12:1031-1033.
4. Bostwick DG, Bensch DG, Burke JF, Billingham MG, Miller DC, Smith J, and Keren DG. Whipple's Disease Presenting as Aortic Insufficiency. N Engl J Med 1981; 305:995-998.
5. Bostwick DG, Egbert BM and Fajardo LF. Radiation Injury of the Normal and Neoplastic Prostate. Am J Surg Pathol 1982; 6:541-551.
6. Roth KA, Evans CJ, Weber E, Barchas D, Bostwick DG, and Bensch KG. Gastrin Releasing Peptide-Related Peptides in a Human Malignant Lung Carcinoid. Cancer Res 1983; 43:5411-5415.
7. Bostwick DG and Fajardo LF. Radiation Injury of the Neoplastic Prostate. American Society of Clinical Pathology (ASCP) Check Sample Series 1983; AP 83-5 (AP-113).
8. Bostwick
DG, Quan R, Hoffman AR, Webber RJ, Chang KJ, and Bensch KG. Growth Hormones
Releasing Factor Immunoreactivity in Human Endocrine Tumors. Am J Pathol
1984; 117: 167-170.
9. Bostwick DG, Bensch KG, Roth KA, Evans CJ, and Barchas JD. Gastrin
Releasing Peptide, a Mammalian Analog of Bombesin, is Present in Human
Neuroendocrine Lung Tumors. Am J Pathol 1984; 117: 29-34,.
10. Bostwick DG, Roth KA, Barchas JD, and Bensch KG. Gastrin Releasing
Peptide Immunoreactivity in Intestinal Carcinoids. Am J Clin Pathol 1984;
82: 428-431.
11. Bostwick DG, Lo R, and Stamey TA. Papillary Adenocarcinoma of the
Male Urethra. Cancer 1984; 54: 2556-2563.
12. Bostwick DG, Kindrachuk RA, and Rouse R. Prostatic Adenocarcinoma
with Endometrioid Features: Clinical Pathology and Ultrastructural Features.
Am J Surg Pathol 1985; 9:595-609.
13. Bostwick DG and Mann RB. Malignant Lymphoma Involving the Prostate:
A Study of 13 Cases. Cancer 1985; 56:195-201.
14. Brawer MK, Peehl DM, Stamey TA, and Bostwick DG. Keratin Immunoreactivity
in Normal and Neoplastic Prostate. Cancer Res 1985; 45:3663-3667.
15. Tazelaar HD, Bostwick DG, Ballon SC, Hendrickson MR, and Kempson RL.
Conservative Treatment of Borderline Ovarian Tumors. Obstet Gynecol 1985;66:
417-422.
16. Weber S, Zuckerman JE, Bostwick DG, Bensch KG, Sikic BI, and Raffin
TA. Gastrin Releasing Peptide is a Selective Mitogen for Small Cell Carcinoma
In Vitro. J Clin Invest 1985; 75:237-244.
17. Bostwick DG and Bensch KG. Gastrin Releasing Peptide in Human Neuroendocrine
Tumors. J Pathol 1985; 147:237-244.
18. Bostwick DG, Tazelaar HD, Ballon SC, Hendrickson MR and Kempson RL.
Ovarian Tumors of Low Malignant Potential: A Clinical and Pathologic Study
of 109 Cases. Cancer 1986; 58: 2052-2065.
19. Panje WR, Moran WJ, and Bostwick DG, Kitt VV. Angiosarcoma of the
Head and Neck: Review of 11 Cases. Laryngoscope 1986; 96:1318-1384,.
20. Brawer MK, Bostwick DG, Peehl DM, and Stamey TA. Keratin Protein in
Human Prostatic Tissue and Cell Culture. Ann NY Acad Sci 1986; 455:729-731.
21. Hallahan DE, Vogelzang NJ, Borow KM, Bowtwick DG, and Simon MA. Cardiac
Metastases from Soft Tissue Sarcomas. J Clinic Oncol 1986;4: 1662-1669.
22. Lynes WL, Bowtwick DG, Freiha FS, and Stamey TA. Parenchymal Brain
Metastases from Adenocarcinoma of Prostate. Urology 1986; 18: 280-287.
23. McNeal JE and Bostwick DG. Intraductal Dysplasia: A Premalignant Lesion
of the Prostate. Human Path 1986; 17:64-71.
24. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FA and Stamey
TA. Patterns of Progression in Prostate Cancer. Lancet 1986; 1: 60-63.
25. Bostwick DG and Brawer MK. Prostatic Intraepithelial Neoplasia and
Early Invasion in Prostate Cancer. Cancer 1987; 59: 788-894.
26. Bostwick DG, Null WE, Holmes D, Weber E, Barchas JD, and Bensch KG.
Expression of Opioid Peptides in Human Tumors. N Engl J Med 1987; 317:1439-1443.
27. Baron B, Bitter M, Joseph M, and Bostwick DG. Gastric Adenocarcinoma
After Gastric Lymphoma. Cancer 1987; 60:1876-1882.
28. Michelassi F, Leuthner S, Lubienski M, Bostwick DG, Rodgers J, Handcock
M, and Block GE. Levels of Ras Oncogene Protein Product Parallel Malignant
Potential of Different Human Colonic Benign Conditions. Arch Surg 1987;
122:1414-1416.
29. Moran WJ, Dobleman TJ, and Bostwick DG. Epithelioid Hamangioendothelioma
(Histiocytoid Hemangioma) of the Palate. Laryngoscope 1987; 97:1299-1302.
30. Chak LY, Cox RS, Bostwick DG, and Hoppe RT. Solitary Plasmacytoma
of Bone: Treatment, Progression, and Survival. J Clin Oncol 1987; 5:1811-1815.
31. Michelassi F, Dieterich M, Montag AG, Bostwick DG, Cliniton SK, Visek
WJ, and Block GE. Increased Levels of ras Oncogene Protein Product in
Carcinogen-Induced Rat Colorectal Adenocarcinomas. Surg Forum 1987; 38:400-402.
32. Carlei F, Lygidakis NJ, Speranza V, Brummelkamp WH, McGurrin JF, and
Lezoche E, Pietroletti R, Bostwick DG. Neuroendocrine Innervation of the
Hepatic Vessels in the Rat and in Man. J Surg Res 1988; 45:417-426.
33. Clinton SK, Bostwick DG, Olson LM, Mangian HJ, and Visek WJ. Ammonia
and Cholic Acid as Promoters of N-Methyl-N-Nitrosoguanidine (MNNG) induced
Colon Carcinogenesis in Rats. Cancer Res 1988; 48:3035-3039.
34. Jockle GA, Lopez I, and Bostwick DG. Campylobacter Pyloridis Associated
Gastritis. American Society of Clinical Pathology (ASCP) Tech Sample Series
1988; HT-6.
35. Tacker JR, Basset JB, Anderson RU, and Bostwick DG. Treatment of Experimental
Bladder Cancer with Hyperthermia and Transitional Phase Liposomes Containing
Methotrexate. J Urol 1988; 139:634-636.
36. Bostwick DG. Premalignant and Other Unusual Lesions of the Prostate.
American Society of Clinical Pathology (ASCP) Check Sample Series, 1988;
TD88-3 (TD8-89).
37. Bostwick DG. Premalignant Lesions of the Prostate. Sem Diag Pathol
1988; 5:254-266.
38. Tetu B, Ro JY, Ayala AG, Srigley JR, Begin LR, and Bostwick DG. Atypical
Spindle Cell Lesions of the Prostate. Sem Diag Pathol 1988; 5:254--266.
39. Bostwick DG. The Pathology of Early Prostate Cancer. CA-A Cancer Journal
for Clinicians 1989; 39:376-393.
40. Bostwick DG. Prostatic Intraepithelial Neoplasia and Early Invasion
in Prostatic Carcinoma. Urology 1989; 34 (6):16-22.
41. Hirsch BZ, Whitington PFR, Kirschner BS, Black DD, Bostwick DG, and
Yousefzadek DK. Isolated Granulomatous Gastritis in an Adolescent. Dig
Dis Sci 1989; 34:292-296.
42. Freije SA, Mostofi RS, and Bostwick DG. Alterations in Glycoconjugate
Expression Following Malignant Transformation of Human Oropharyngeal Squamous
Mucosa. Laryngoscope 1989; 99:197-203.
43. Berkelhammer CH, Baker AL, Block GE, Bostwick DB, and Michelassi F.
Humoral Hypercalcemia Complicating Adenosquamous Carcinoma of the Proximal
Colon. Dig Dis Sci 1989; 34:142-147.
44. Dieterich M, Clinton SK, Olson LM, Erroi F, Bostwick DG, Montag AG,
and Visek WJ. Expression of Ras Oncogene in N-Methyl-N-Nitrosoguanidine-Induced
Rat Colon Tumors Res Surg 1989; 1:113-117.
45. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP.
The Association of Benign Prostatic Hyperplasia and Cancer of the Prostate.
Cancer 70:291-301, 1992
46. Bostwick DG. Prostatic Intraepithelial Neoplasia (PIN): Current Concepts.
J Cell Biochem 1992;16H:10-19.
47. Bostwick DG. Natural History of Early Bladder Cancer. J Cell Biochem
1992; 16I:31-38.
48. Bostwick DG, Bose D, Srigley J, Grignon D, Maksem J, van der Kwast
T, Humphrey P, Young R. Atypical Adenomatous Hyperplasia (AAH) of the
Prostate: Morphologic Criteria for its Distinction from Well-Differentiated
Carcinoma. Human Pathol 1993; 24:819-832.
49. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural
Patterns of High Grade Prostatic Intraepithelial Neoplasia. Human Pathol
1993; 24:298-310.
50. Bostwick DG, Graham SD, Napalkov P, Abrahamsson PA, di Sant'Agnese
PA, Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder
F, Murphy GP. Staging of Early Prostate Cancer: A Proposed Tumor Volume-Based
Prognostic Index. Urology 1993; 41:403-411.
51. Durham JR, Bostwick DG, Farrow GM, Ohorodnik JM. Mesoblastic Nephroma
of Adulthood. Report of Three Cases. Am J Surg Pathol 1993; 17:1029-1038.
52. Devaraj LT and Bostwick DG. Atypical Basal Cell Hyperplasia and Adenoid
Basal Cell Tumor of the Prostate: Immunophenotypic Profile and Proposed
Classification. Am J Surg Pathol 1993; 17:645-659.
53. Bovenberg SA, van der Zwet CJJ, van der Kwast TH, Marzella L, and
Bostwick DG. Prostate Specific Antigen Expression in Prostate Cancer and
Its Metastases
J Urologic Pathol 1993; 1:55-61.
54. Fain JS, Cosnow I, King BF, Zincke H, Bostwick DG. Cystosarcoma Phyllodes
of the Seminal Vesicle. Cancer 1993; 71:2055-2061.
55. Bostwick DG and de La Roza G. Intraepithelial Neoplasia: A Call for
Standardized Terminology. J Urologic Pathol 1993; 1:95-103.
56. Oesterling JE, Suman VJ, Bostwick DG. PSA-Detected (Clinical Stage
T1c or B0) Prostate Cancer. Urol Clin N Amer 1993; 20:687-693.
57. Bostwick DG, Myers RP, Oesterling JE. The Staging of Prostate Cancer.
Seminars in Surgical Oncology 1994; 10:60-72.
58. Adalkha H, Bostwick DG. Paneth Cell-Like Change in Prostatic Adenocarcinoma
Represents Neuroendocrine Differentiation: Report of 30 Cases. Hum Pathol
1994; 25:135-139.
59. Bostwick DG, Al Annouf N, Choi C. Establishment of the Formalin-Free
Surgical Pathology Laboratory. Utility of an Alcohol-Based Fixative. Arch
Pathol Lab Med 1994; 118:298-302.
60. Sebo TJ, Bostwick DG, Farrow GM, Eble JN. Prostatic Xanthoma: A Mimic
of Prostatic Adenocarcinoma. Hum Pathol 1994; 25:386-389.
61. Blackwell KL, Bostwick DG, Zincke H, Myers, RP, Oesterling JE. Combining
Prostate Specific Antigen with Cancer and Gland Volume to More Reliably
Predict Pathologic Stage: The Influence of PSA-Cancer Density. J Urol
1994;151:1565-1570.
62. Chiang KS, LeRoy AJ, Swee R, Bostwick DG. Erdheim-Chester Disease
Presenting as Retroperitoneal Xanthogranulomatosis. J Comp Assisted Tomography
1994; 18:503-506.
63. Bostwick DG. Gleason Grading of Prostatic Needle Biopsies: Correlation
with Grade in 316 Matched Prostatectomies. Am J Surg Pathol 1994; 18:796-803.
64. Ferguson J, Bostwick DG, Ellison E, Bergstrahl, Zincke H. Decrease
of Prostatic Intraepithelial Neoplasia (PIN) Following Androgen Deprivation
Therapy in Patients with Stage T3 Prostatic Adenocarcinoma. J Urol 1994;
44:91-95.
65. Bostwick DG. Standardization and Quality Control of Surrogate Endpoint
Biomarkers Assays for Prostate Cancer. J Cell Biochem, 1994: suppl. 19;
189-190.
66. Bostwick DG. Target Populations and Strategies for Chemoprevention
Trials of Prostate Cancer. J Cell Biochem, 1994: suppl. 19;191-196.
67. Bostwick DG. Current and Proposed Biologic Markers in Prostate Cancer:
1994.
J Cell Biochem 1994: suppl. 19;197-201.
68. Bostwick DG. The Most Promising Surrogate Endpoint Biomarkers for
Screening Candidate Chemopreventive Compounds for Prostatic Adenocarcinoma
in Short-Term Phase II Clinical Trials. J Cell Biochem 1994: suppl. 19;283-289.
69. Bostwick DG. Prostate-Specific Antigen. Current Role in Diagnostic
Pathology of Prostate Cancer. Am J Clin Pathol 1994; 102(4):S31-S37.
70. Bostwick DG. Grading Prostate Cancer. Am J Clin Pathol 1994; 102(4):S38-S56.
71. Bostwick DG, Dousa MK, Crawford BG, Wollan PC. Neuroendocrine Differentiation
in Prostatic Intraepithelial Neoplasia and Adenocarcinoma. Am J Surg Pathol
1994; 18:1240-1246.
72. Bostwick DG, Vonk JB, Picado A. Pathologic Changes in the Prostate
Following Contemporary 18 Gauge Needle Biopsy: No Apparent Risk of Local
Cancer Seeding. J Urol Pathol 1994: 2: 203-211.
73. Gierke CL, King BF, Bostwick DG, Choyke PL, and Hattery RR: Large-Cell
Calcifying Sertoli Cell Tumor of the Testis: Appearance at Sonography.
Am J Roentg 1994: 163:373-375.
74. Bluestein DL, Bostwick DG, Bergstralh E, and Oesterling JE: Eliminating
the Need for Bilateral Pelvic Lymphadenectomy in Select Patients With
Prostate Cancer.
J Urol 1994; 151:1315-1320.
75. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM,
Jenkins RB. Potential Markers of Prostate Cancer Aggressiveness Detected
by Fluorescence In Situ Hybridization in Needle Biopsies. Cancer Res 1994,
54:3574-3579.
76. Bostwick DG. c-erbB-2 oncogene expression in prostatic intraepithelial
neoplasia: mounting evidence for a precursor role J Natl Cancer Inst 1994;
86: p. 1108-1110.
77. Bostwick DG. High Grade Prostatic Intraepithelial Neoplasia: The Most
Likely Precursor of Prostate Cancer. Cancer 1995; 75:1823-1836.
78. Bostwick DG and Larson TR. Transurethral Microwave Thermal Therapy:
Pathologic Findings in the Canine Prostate. Prostate 1995; 26:116-122.
79. Kletscher BA, Qian J, Bostwick DG, Andrews PE, Zincke H. Prospective
Analysis of Multifocality in Renal Cell Carcinoma: Influence of Histological
Pattern, Grade, Number, Size, Volume, and Deoxyribonucleic Acid Ploidy.
J Urol 1995; 153:904-906.
80. Bostwick DG, Qian J. Atypical Adenomatous Hyperplasia of the Prostate.
Relationship with Carcinoma in 217 Whole-mount Radical Prostatectomies.
Am J Surg Pathol 1995; 19:506-518.
81. Bostwick DG, Wollan P, Adlakha K. Collagenous Micronodules in Prostate
Cancer. A Specific but Infrequent Diagnostic Finding. Arch Pathol Lab
Med 1995; 119:444-447.
82. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence
CD, Zhuang A, Bostwick DG, Liotta LA, Linehan WM. Allelic Loss on Chromsome
8p12-21 in Microdissected Prostatic Intraepithelial Neoplasia. Cancer
Res 1995; 55:2959-2962.
83. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The Volume of Prostate
Cancer in the Biopsy Specimen Cannot Reliably Predict the Quantity of
Cancer in the Radical Prostatectomy Specimen on an Individual Basis. J
Urol 1995;153:1543-1548.
84. Bostwick DG. Clinical Utility of Prostatic Intraepithelial Neoplasia.
Mayo Clin Proc 1995; 395-396.
85. Bostwick DG. The Pathology of Incidental Carcinoma. Cancer Surveys
1995; 23:7-18.
86. Bostwick DG, Leske DA, Qian J, Sinha AA. Prostatic Intraepithelial
Neoplasia and Well Differentiated Adenocarcinoma Maintain an Intact Basement
Membrane. Path Res Pract 1995; 191:850-855.
87. Qian J, Bostwick DG. The Extent and Zonal Location of Prostatic Intraepithelial
Neoplasia and Atypical Adenomatous Hyperplasia: Relationship with Carcinoma
in Radical Prostatectomy Specimens. Path Res Pract 1995; 191:860-867.
88. Ferguson JK, Bostwick DG, Suman V, Zincke H, Oesterling JE. Prostate-Specific
Antigen Detected Prostate Cancer: Pathological Characteristics of Ultrasound
Visible Versus Ultrasound Invisible Tumors. Eur Urol 1995; 27:8-12.
89. Qian J, Jenkins RB, Bostwick DG. Chromosomal Anomalies in Atypical
Adenomatous Hyperplasia and Carcinoma of the Prostate Detected by Fluorescence
In Situ Hybridization. Urology 1995; 46:837-842.
90. Goldstein N, Qian J, Bostwick DG. Mucin in Atypical Adenomatous Hyperplasia.
Hum Pathol 1995; 26:887-891.
91. Bostwick DG, Frankel K, Qian J. The Incidence of High Grade Prostatic
Intraepithelial Neoplasia and Cancer in Contemporary Needle Biopsies.
Hum Pathol 1995; 154:1791-1794.
92. Dundore PA, Nascimento AG, Cheville JC, Bostwick DG. Carcinosarcoma
of the Prostate. Report of 21 Cases. Cancer 1995; 76:1035-1042.
93. Davidson D, Bostwick DG, Qian J, Wollan P, Oesterling JE, Rudders
RA, Siroky M, Stilmant M. Prostatic Intraepithelial Neoplasia is a Risk
Factor for Adenocarcinoma: Predictive Accuracy in Needle Biopsies. J Urol
1995; 154:1295-1299.
94. Cheville JC, Bostwick DG. Post-atrophic Hyperplasia of the Prostate.
Am J Surg Pathol 1995; 1068-1076.
95. Salomao DR, Graham SD, Bostwick DG. Microvascular Invasion in Prostate
Cancer Correlates with Pathologic Stage. Arch Pathol Lab Med 1995; 119:1050-1054.
96. Ferreiro JA, Myers JL, Bostwick DG. Accuracy of Frozen Section in
Surgical Pathology: Review of a 1-Year Experience with 24,880 Cases at
Mayo Clinic Rochester. Mayo Clin Proc 1995; 70:1137-1141.
97. Ferreiro JA, Gisvold JJ, Bostwick DG. Accuracy of Frozen-section Diagnosis
of Mammographically Directed Breast Biopsies. Results of 1,490 Consecutive
Cases. Am J Surg Pathol 1995; 19:1267-1271.
98. Cheville JC, Dundore PA, Nascimento AG, Meneses M, Kleer E, Farrow
GM, and Bostwick DG. Leiomyosarcoma of the Prostate: Report of 23 Cases.
Cancer 1995; 76:1422-1427.
99. Helpap BG, Bostwick DG, Montironi R. The Significance of Atypical
Adenomatous Hyperplasia and Prostatic Intraepithelial Neoplasia for the
Development of Prostate Carcinoma. An Update. Virchows Arch 1995;426:425-434.
100. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber
MM, Thibodeau SN, Jenkins RB. Frequent Loss of Heterozygosity at 7q31.1
in Primary Prostate Cancer is Associated with Tumor Aggressiveness and
Progression. Cancer Res 1995; 55:4114-4119.
101. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG.
Minimal or No Cancer in Radical Prostatectomy Specimens: Report of 13
Cases of the “Vanishing Cancer Phenomenon.” Am J Surg Pathol
1995; 19:1002-1009.
102. Monda JM, Myers RP, Bostwick, DG, Oesterling JE. The Correlation
Between Serum Prostate-Specific Antigen and Prostate Cancer is Not Influenced
by the Serum Testosterone Concentration. Urology 1995; 46:62-4.
103. Schneider BG, Pulitzer DR, Brown RD, Prihoda TJ, Bostwick DG, Saldivar
V, Rodriguez-Martinez HA, Gutierrez-Diaz ME, O’Connell P. Allelic
Imbalance in Gastric Cancer: An affected Site on Chromosome Arm 3p. Genes,
Chromosomes & Cancer 1995; 13: 263-71.
104. Monda JM, Myers RP, Bostwick DG, Oesterling JE. The Correlation Between
Serum Prostate-Specific Antigen and Prostate Cancer is not Influenced
by the Serum Testosterone Concentration. Urology 1995; 46:62-4.
105. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Dundore P,
Myers RP, Oesterling JE. The definition and Preoperative Prediction of
Clinically Insignificant Prostate Cancer. JAMA 1996; 275:288-294.
106. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling
JE. Correlation of Pretherapy Prostate Cancer Characteristics with Histologic
Findings From Pelvic Lymphadenectomy Specimens. Int J Rad Oncol Biol Phys
1996; 34:33-39.
107. Bostwick DG, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP,
Oesterling JE. Prediction of Capsular Perforation and Seminal Vesicle
Invasion in Prostate Cancer. J Urol 1996;155:1361-1367.
108. Gould VE, Doljanskaia V, Gooch G, Bostwick DG. Immunolocalization
of Glycoprotein A-80 in Prostatic Carcinoma and Prostatic Intraepithelial
Neoplasia. Hum Pathol 1996; 27:547-552.
109. Alexander EE, Qian J, Wollan PC, Myers RP, Bostwick DG. Prostatic
Intraepithelial Neoplasia Does Not Appear to Raise Serum Prostate-Specific
Antigen Concentration. Urology 1996; 47:693-698.
110. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup
SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. Analysis of 99 Microdissected
Prostate Carcinomas Reveals a High Frequency of Allelic Loss on Chromosome
8p12-21. Cancer Res 1996; 56:2411-2416.
111. Graham SD Jr, Napalkov P, Watts L, Salomao D, Bostwick DG. Microvascular
Invasion of the Seminal Vesicles in Adenocarcinoma of the Prostate. Prostate
1996; 28:359-363.
112. Brown JA, Takahashi S, Alcaraz A, Borell TJ, Anderl KL, Qian J, Persons
DL, Bostwick DG, Lieber MM, Jenkins RB. Fluorescence In Situ Hybridization
Analysis of Renal Oncocytoma Reveals Frequent Loss of Chromosomes Y and
1.
J Urol 1996; 156:31-35.
113. Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular Biology of Prostatic
Intraepithelial Neoplasia. Prostate 1996; 29:117-134.
114. Ellison E, Chuang SS, Zincke H, Ferguson, Bostwick DG. Prostate Adenocarcinoma
After Androgen Deprivation Therapy: A Comparative Study of Morphology,
Morphometry, Immunohistochemistry, and DNA Ploidy. Pathology Case Reviews
1996; 1:74-83.
115. Amin MB, Bostwick DG. Pigment in Prostatic Epithelium and Adenocarcinoma:
A Potential Source of Diagnostic Confusion with Seminal Vesicular Epithelium.
Mod Pathol 1996; 9:791-795.
116. Chen W, Weghorst CH, Sabopurin CLK, Wang Y, Bostwick DG, Stoner D.
Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis
1996; 17:2603-2607.
117. Bostwick DG, Aquilina JW. Prostatic Intraepithelial Neoplasia (PIN)
and Other Prostatic Lesions as Risk Factors and Surrogate Endpoints for
Cancer Chemoprevention Trials. J Cell Biochem 1996; 25S:156-164.
118. Qian J, Jenkins RB, Bostwick DG. Potential Markers of Aggressiveness
in Prostatic Intraepithelial Neoplasia Detected by Fluorescence in Situ
Hybridization. Euro Urol 1996; 30:177-184.
119. Larson TR, Bostwick DG, Corica A. Temperature-Correlated Histopathologic
Changes Following Microwave Thermoblation of Obstructive Tissue in Patients
with Benign Prostatic Hyperplasia. Urology 1996; 47:463-469.
120. Clinton SK, Emenhiser C, Schwartz SJ, Bostwick DG, Williams AW, Moore
BJ, Erdman JW Jr. cis-trans Lycopene Isomers, Carotenoids, and Retinol
in the Human Prostate. Cancer Epid Biomark Prev 1996; 5:823-833.
121. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM,
Jenkins RB. Comparison of Fluorescence in Situ Hybridization Analysis
of Isolated Nuclei and Routine Histological Sections from Paraffin-Embedded
Prostatic Adenocarcinoma Specimens. Am J Pathol 1996; 149:1193-1199.
122. Kuntzman TS, Malek RS, Barrett DM, Bostwick DG. Potassium-Titanyl-Phosphate
Laser Vaporization of the Prostate: A Comparative Functional and Pathologic
Study in Dogs. Urology 1996; 48:575-583.
123. Bostwick DG, Guthman DA, Letendre L, Banks PM, Texter JH Jr, Lieber
MM. Polymphorphic Reticulosis (Idiopathic Midline Destructive Disease)
of the Penis, Scrotum, and Perineum. J Urol Pathol 1996; 5:57-63.
124. Bostwick DG. Progresssion of Prostatic Intraepithelial Neoplasia
to Early Invasive Adenocarcinoma. Euro Urol 1996; 30:145-152.
125. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ,
Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN. Allelic Imbalance
and Microsatellite Instability in Prostatic Adenocarcinoma Cancer Res
1996; 56:4475-4482.
126. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H.
Correlation of Pretherapy Prostate Cancer Characteristics with Seminal
Vesicle Invasion in Radical Prostatectomy Specimens. Int J Rad Oncol Biol
Phys 1996; 36:585-591.
127. Young RH, Bostwick DG. Florid Cystitis Glandularis of Intestinal
Type with Mucin Expression. Am J Surg Pathol 1996; 20:1462-1468.
128. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo
TJ,. Scardino PT, , Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford
ED, Blumenstein BA, Mahran HE, Miles BJ. Optimized Microvessel Density
Analysis Improves Prediction of Cancer Stage from Prostate Needle Biopsies.
Urology 1996; 48:47-57.
129. Harmon WJ, Barrett DM, Qian J, Lauvetz RW, Bostwick DG, Gokcen M.
Transurethral Enzymatic Ablation of the Prostate (TEAP): Canine Model.
Urology 1996; 48:47-57.
130. Burke HB, Goodman PH, Rosen DB, Henson DE, Weinstein JN, Harrell
FE Jr, Marks JR, Winchester DP, Bostwick DG. Artificial Neural Networks
Improve the Accuracy of Cancer Survival Prediction. Cancer 1996; 79:857-62.
131. Bostwick DG, Aquilina JW. Prostatic Intraepithelial neoplasia (PIN)
and Other Prostatic Lesions as Risk Factors and Surrogate Endpoints for
Cancer Chemoprevention Trials. J. Cell Biochem (suppl) 1996; 25:156-64.
132. Allam CK, Bostwick DG, Hayes JA, Upton MP, Wade GG, Domanowski GF,
Klein MA, Boling EA, Stilmant MM. Interobserver Variability in the Diagnosis
of High-grade Prostatic Intraepithelial Neoplasia and Adenocarcinoma.
Mod Pathol 1996; 9:742-51.
133. Harmon WJ, Barrett DM, Qian J, Lauvetz RW, Bostwick DG, Gocken M.
Transurethral Enzymatic Ablation of the Prostate: Canine Model. Urology
1996; 48:229-33.
134. Montironi R, Bostwick DG, Bonkhoff H, Cockett AT, Helpap B, Troncoso
P, Waters D. Origins of Prostate Cancer. Cancer 1996; 78: 362-5.
135. Bostwick DG. Prospective Origins of Prostate Carcinoma. Prostatic
Intraepithelial Neoplasia and Atypical Adenomatous Hyperplasia. Cancer
1996; 78:330-6.
136. Amin MB, Grignon D, Bostwick DG, Reuter V, Troncoso P, Ayala AG.
Recommendations for the Reporting of Resected Prostate Carcinomas. Association
of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1996;
105:667-70.
137. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke
H. Analysis of Risk Factors for Progression in Patients with Pathologically
Confirmed Prostate Cancers After Radical Retropubic Prostatectomy. J Urol
1996; 156:137-43.
138. Bostwick DG, Qian J, Bergstralh E, Dundore P, Dugan J, Myers RP,
Oesterling JE. Prediction of Capsular Perforation and Seminal Vesicle
Invasion in Prostate Cancer. J Urol 1996; 155:1361-7.
139. Kletscher BA, Qian J, Bostwick DG, Blute ML, Zincke H. Prospective Analysis of the Incidence of Ipsilateral Adrenal Metastasis in Localized Renal Cell Carcinoma. J Urol 1996; 155:1844-6.
140. Bostwick
DG. Staging Prostate Cancer, 1997: Current Methods and Limitations. Eur
Urol 32(supp 3):2-14, 1997.
141. Aquilina JW, Lipsky JJ, Bostwick DG. Androgen Deprivation as a Strategy
for Prostate Cancer Chemoprevention. J National Cancer Institute 89:689-696,
1997.
142. Egan AJM, Lopez-Beltran A, Bostwick DG. Prostatic Adenocarcinoma
with Atrophic Features. Malignancy Mimicking a Benign Process. Am J Surg
Pathol 21:931-935, 1997.
143. Pacelli A, Bostwick DG. The Clinical Significance of High-Grade Prostatic
Intraepithelial Neoplasia in Transurethral Resection Specimens. Urology
50:355-359, 1997.
144. Cheville JC, Clark JR, Neitzel GF, Reznicek M, Bostwick DG. The Focus
of Atypical Glands Suspicious for Malignancy in Prostate Needle Biopsy
Specimens: Incidence, Histologic Features, and Clinical Follow-up of Cases
Seen in a Community Practice. Am J Clin Pathol 108:633-640, 1997.
145. MacLennan GT, Farrow GM, Bostwick DG. The Immunophenotype of Renal
Cell Carcinoma: Comparative Profiles of the Main Histologic Types Based
on Study of 60 Cases. J Urol Pathol 6, 195-204, 1997.
146. Schleicher RL, Hunter SH, Bandea CI, Zhang CI, Zheng M, Tan W, Fallon
MT, Bostwick DG, Varma VA. Neurofilament Heavy Chain-Like mRNA and Protein
are Present in Benign Prostate and Downregulated in Prostatic Carcinoma.
Cancer Res 57:3532-3526, 1997.
147. MacLennan GT, Farrow GM, de Matteis A, Bostwick DG. Collecting Duct
Carcinoma of the Kidney: Critical Analysis of Factors Influencing Prognosis
with Emphasis on Well Differentiated Carcinoma. Am J Surg Pathol 6:195-204,
1997.
148. Kuntzman, R., Malek R., Bostwick D.G., 60 Watt KP/532 Laser Vaporization
Prostatectomy: Observations in Living and Cadaveric Canine and Cadaveric
Human Prostate. Urology 49:703-708, 1997.
149. Iczkowski KA, Kiviat J, Cheville JC, Bostwick DG. Multifocal Capillary
Micro-angioma of the Testis. J. Urol Pathol. 7:113-120, 1997.
150. Qian J, Jenkins RB, Bostwick DG. Detection of Chromosomal Anomalies
c-myc Gene Amplification in the Cribriform Pattern of Prostatic Intraepithelial
Neoplasia and Carcinoma by Fluorescence In Situ Hybridization. Mod Path
10:1113-1119, 1997.
151. Bostwick DG, Iczkowski KA. Minimal Criteria for the Diagnosis of
Prostate Cancer on Needle Biopsy. Annals of Diagnostic Pathology 2: 104-129,
1997.
152. Bostwick DG, Aquilina JW, Finasteride Shows Modest Pathologic Changes
in Prostate Cancer. J Urol Pathol 1997; 6:83-84.
153. Kerley SV, Corica FA, Qian J, Myers RP, Bostwick DG. Peripheral Zone
Involvement by Prostatic Hyperplasia. J Urol Pathol 1997; 6:87-94.
154. Kempton CL, Kurtin PJ, Inwards DJ, Wollan P, Bostwick DG. Malignant
Lymphoma of the bladder: Evidence From 36 Cases That Low-Grade Lymphoma
of the MALT-type is the Most Common Primary Bladder Lymphoma. Am J Surg
Pathol 21:1324-33, 1997.
155. Burke HB, Goodman PH, Rosen, DB, Henson DE, Weinstein JN, Harrell
FE Jr, Marks JR, Winchester DP, Bostwick DG. Artifical Neural Networks
Improve the Accuracy of Cancer Survival Prediction. Cancer 79:857-62,
1997.
156. Bostwick DG. Evaluating Prostate Needle Biopsy: Therapeutic and Prognostic
Importance. CA: A Cancer Journal For Clinicians 47:297-319, 1997.
157. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson
M, Delahunt B, Iczkowski K. Classification of Renal Cell Carcinoma: Workgroup
No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint
Committee on Cancer (AJCC). Cancer 80:987-9, 1997.
158. Corica FA, Husmann DA, Churchill BM, Young RH, Pacelli A, Lopez-Beltran
A, Bostwick DG. Intestinal Metaplasia is Not a Strong Risk Factor For
Bladder Cancer: Study of 53 Cases With Long-Term Follow-Up. Urology 50:427-31,
1997.
159. Bostwick DG, Pacelli A, Lopez-Beltran A. Ultrastructure of Prostate
Intraepithelial Neoplasia. Prostate 33: 32-77, 1997.
160. Helpap B, Bonkhoff H, Cockett A, Montironi R, Troncoso P, Waters
D, Bostwick DG. Relationship Between Atypical Adenomatous Hyperplasia
(AAH), Prostatic Intraepithelial Neoplasia (PIN) and Prostatic Adenocarcinoma.
Pathologica 89:288-300, 1997.
161. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhuang Z, Duray PH, Bostwick
DG, Linehan, WM, Liotta, LA. Identification of a Novel Transcript Up-Regulated
in a Clinically Aggressive Prostate Carcinoma. Urology 50:302-7, 1997.
162. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS,
Curtis RT, Shell RT, Shell BK, Bostwick DG, Tindall DJ, Gelmann EP, Abate-Shen
C, Carter KC. A Novel Human Prostate-Specific, Androgen-Regulated Homeobox
Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate
Cancer. Genomics 43:69-77, 1997.
163. Brown JA, Anderl KL, Borell TJ, Qian J, Bostwick DG. Simultaneous
Chromosome 7 and 17 Gain and Sex Chromosome Loss Provide Evidence That
Renal Metanephric Adenoma is Related to Papillary Renal Cell Carcinoma.
J of Urol 158:370-4, 1997.
164. Roberts RO, Lieber MM, Bostwick DG, Jacobsen SJ. A Review of Clinical
and Pathological Prostatitis Syndromes. Urology 49:809-21, 1997.
165. Waters DJ, Bostwick DG. The Canine Prostate is a Spontaneous Model
of Intraepithelial Neoplasia and Prostate Cancer Progression. Anticancer
Research 17:1467-70, 1997.
166. Pisansky TM, Kahn MJ, Bostwick DG. An Enhanced Prognostic System
for Clinically Localized Carcinoma of the Prostate. Cancer 79:2154-61,
1997.
167. Bostwick DG, Montironi R. Evaluating Radical Prostatectomy Specimens:
Therapeutic and Prognostic Importance. Virchows Archiv. 430:1-16, 1997.
168. Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco
RE, Bostwick DG. Diagnosis of “Suspicious for Malignancy”
in Prostate Biopsies: Predictive Value for Cancer. Urology. 51:749-758,
1998.
169. Bostwick DG. Practical clinical application of predictive factors
in prostate cancer. A review with an emphasis on quantitative methods
in tissue specimens. Anal Quant Cytol Histol. 20: 323-342, 1998.170. Burke
HH, Bostwick DG ProstAsure Index in the Detection of Prostate Cancer.
Urology 1999.
171. Aquilina JW, McKinney L, Pacelli A, Richman LK, Waters DJ, Thompson
I, Burghardt WF Jr, Bostwick DG High Grade Prostatic Intraepithelial Neoplasia
in Military Working Dogs With and Without Prostate Cancer. Urology, 36:189-193,
1998.
172. Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP, Bostwick DG.
Correlation of margin status and extraprostatic extension with progression
of prostate carcinoma. Cancer 1999;86:2102-2108
173. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder
P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine
kinase in prostate cancer. Prostate 1999;41:275-80
174. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL,
Scherer BG, Blute ML, Zincke H, Bostwick DG. Cell proliferation in prostate
cancer patients with lymph node metastasis: a marker for progression.
Clin Cancer Res 1999; 5:2820-2823.
175. Cheng L, Cheville JC, Bostwick DG. Diagnosis of prostate cancer in
needle biopsies after radiation therapy. Am J Surg Pathol 1999 Oct;23(10):1173-83
176. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting
Cancer Progression in Patients With Stage T1 Bladder Carcinoma. J Clin
Oncol 1999 Oct;17(10):3182-3187
177. Bostwick DG, Eble JN. Diagnosis and classification of renal cell
carcinoma. . Urol Clin North Am 1999 Aug;26(3):627-35
178. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder
cancer and associated lesions. Urol Clin North Am 1999 Aug;26(3):493-507
179. Bostwick DG, Ramnani D, Cheng L. Treatment changes in prostatic hyperplasia
and cancer, including androgen deprivation therapy and radiotherapy. Urol
Clin North Am 1999 Aug;26(3):465-79
180. Iczkowski KA, Bostwick DG. Prostate biopsy interpretation. Current
concepts, 1999. Urol Clin North Am 1999 Aug;26(3):435-52
181. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick
DG, Grizzle WE. Ep-Cam levels in prostatic adenocarcinoma and prostatic
intraepithelial neoplasia. J Urol 1999 Oct;162(4):1462-6
182. Cheng L, Weaver AL, Neumann RM, Scherer BG, Bostwick DG. Substaging
of T1 bladder carcinoma based on the depth of invasion as measured by
micrometer: A new proposal. Cancer 1999; 86:1035-43
183. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression
of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42:
73-78
184. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ,
Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade,
advanced, nonmetastatic prostate carcinoma. . J Natl Cancer Inst 1999;
91:1574-80
185. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H,
Bostwick DG. Role of microvessel density in predicting recurrence in pathologic
Stage T3 prostatic adenocarcinoma. Urology 1999; 54:479-85
186. Bostwick DG. What is the significance of race to prostate carcinoma?
Cancer 1999; 86:735-7
187. Iczkowski KA, Shanks JH, Allsbrook WC, Lopez-Beltran A, Pantazis
CG, Collins TR, Wetherington RW, Bostwick DG. Small cell carcinoma of
urinary bladder is differentiated from urothelial carcinoma by chromogranin
expression, absence of CD44 variant 6 expression, a unique pattern of
cytokeratin expression, and more intense gamma-enolase expression. Histopathology
1999; 35:150-6
188. Afonso A, Emmert-Buck MR, Duray PH, Bostwick DG, Linehan WM, Vocke
CD. Loss of heterozygosity on chromosome 13 is associated with advanced
stage prostate cancer. J Urol 1999; 162(3 Pt 1):922-6
189. Nehra A, Gettman MT, Nugent M, Bostwick DG, Barrett DM, Goldstein
I, Krane RJ, Moreland RB. Transforming growth factor-beta1 (TGF-beta1)
is sufficient to induce fibrosis of rabbit corpus cavernosum in vivo.
J Urol 1999; 162:910-5
190. Cheng L, Slezak J, Bergstralh EJ, Cheville JC, Sweat S, Zincke H,
Bostwick DG. Dedifferentiation in the metastatic progression of prostate
carcinoma. Cancer 1999; 86:657-63
191. Strup SE, Pozzatti RO, Florence CD, Emmert-Buck MR, Duray PH, Liotta
LA, Bostwick DG, Linehan WM, Vocke CD. Chromosome 16 allelic loss analysis
of a large set of microdissected prostate carcinomas. J Urol 1999; 162:590-594
192. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist?
Am J Surg Pathol 1999;23:781-785
193. Dechet CB, Bostwick DG, Blute ML, Bryant SC, Zincke H. Renal oncocytoma:
multifocality, bilateralism, metachronous tumor development and coexistent
renal cell carcinoma. J Urol 1999;162:40-42
194. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman
DW, Sargent DJ, Bostwick DG. The radial distance of extraprostatic extension
of prostate carcinoma: implications for prostate brachytherapy. Cancer
1999; 85:2630-2637
195. Bostwick DG, Neumann R, Qian J, Cheng L. Reversibility of prostatic
intraepithelial neoplasia: implications for chemoprevention. Eur Urol
1999;35:492-495
196. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms
of low malignant potential: clinical and biologic implicatioins. Cancer
86: 2102-2108, 1999.
197. Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, Bostwick
DG. Urothelial papilloma of the bladder: clinical and biologic implications.
Cancer 86: 2098-2101, 1999.
198. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer
JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2)
in human invasive transitional cell carcinoma (TCC) of the urinary bladder.
Cancer Res 1999; 59:5647-5650.
199. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman
MG, Pisansky TM. Treatment of extraprostatic cancer in clinically organ
confined prostate cancer by permanent prostate brachytherapy: Is extraprostatic
seed placement necessary? (submitted 2000)
200. Davis BJ, Pisansky TM, Haddock MG, Wilson TM, Sargent DJ, Hillman
DW, Herman MG, Bostwick DG. Examining prostate brachytherapy patient selection
criteria as applied to prostatectomy findings: Rationale for broadening
eligibility for monotherapy. (submitted 2000).
201. Wang L, darling J, Zhang JS, Liu W, Qian J, Bostwick DG, Hartmann
L, Jenkins R, Bardenhauer W, Schutte J, Palka B, Smith DI. Loss of expression
of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma.
Genes Chromosomes Cancer 27: 1-10, 2000.
202. Bostwick DG, Ramnani D, Qian J. Prostatic intraepithelial neoplasia:
Animal models 2000. Prostate 2000 (in press)
Books
1. Bostwick
DG and Rosenbloom AJ. Official Bicycling Guide to Maryland, Baltimore
News American, 1976; endorsed by the Maryland Commission on Physical Fitness
and the Maryland State Department of Tourism.
2. Bostwick DG, Microwave Oven Methods in Pathology, Stat Path Press,
Riderwood, MD, 1987.
3. Bostwick DG (Editor), Pathology of the Prostate, Churchill Livingstone,
New York, NY, 1990.
4. Bostwick DG, MacLennan GM, Larson TA. The American Cancer Society Guide
to Prostate Cancer. Villiard Press (Random House), NY, NY, 1996; second
edition, 1999.
5. Bostwick DG, Eble J. (Editors) Urologic Surgical Pathology, Mosby-Year
Book Publishers, Inc., St. Louis, MO, 1997.
6. Bostwick DG, Dundore PA. Prostate Biopsy Interpretation. Chapman-Hall
Publishers, Inc., London, England, 1997.
7. Foster CS, Bostwick DG (Editors) Pathology of the Prostate, W.B. Saunders,
Philadelphia, PA, 1998.
8. Bostwick DG, Lopez-Beltran A. Bladder Biopsy Interpretation. United
Pathologists Press, Tampa, FL, 1999.
9. Cheng L, Bostwick DG. Essentials of Diagnostic Pathology (in final
preparation)
Book Chapters
1. Bostwick
DG. Origins of Prostatic Carcinoma. In: Progress in Reproductive and Urinary
Tract Pathology, Vol. I, Eds. Damjanov I. Cohen AH, Mills SE, and Young
RH. Field and Wood, New York, NY, 1989.
2. Mills SE, Bostwick DG, Murphy W, and Weiss M. Symposium on Pathology
of the Prostate. In: Pathology Annual, Eds. Fechner RE and Rosen PP. Williams
and Wilkens, Baltimore, MD, 1990.
3. Bostwick DG and Choi C. Prognostic Factors in Prostate Cancer. In:
Urology Annual, Ed. S. Rous, Norton Medical Books, Philadelphia, PA (1992).
4. Murphy GP, Oesterling JE, Algaba F, Bodrogi I, Bostwick DG, et al.
Prostate Specific Antigen: Pertinent Issues For Distinguished Prostate
Cancer From Benign Prostatic Hyperplasia. In: Proceedings - The International
Consultation on Benign Prostatic Hyperplasia. Ed. Cockett ATK et al.,
Scientific Communication International (1993) pp. 229-252.
5. Mostofi FK, Sesterhenn IA, Algaba F, Bostwick DG. Pathology of Benign
Enlargement of the Prostate. In: Proceedings - The International Consultation
on Benign Prostatic Hyperplasia. Ed. Cockett ATK et al., Scientific Communication
International (1993) pp. 515-537.
6. Bostwick DG. Significance of Tumor Volume in Prostate Cancer. In: Urology
Annual, Ed. S. Rous, Norton Medical Books, Philadelphia, PA (1994) pp.
1-22.
7. Bostwick DG, Amin MB. Pathology of the Prostate and Seminal Vesicles.
In: Anderson's Textbook of Pathology, Eds. Damjanov I, Lindner J. Mosby-Year
Book Publishers, Inc., St. Louis, MO (1995).
8. Bostwick DG. Prostatic Intraepithelial Neoplasia. In: Comprehensive
Textbook of Genitourinary Oncology, Eds. Vogelzang NJ, Scardino PT, Shipley
WS, Coffey DS. Williams and Wilkins, Baltimore, MD (1995). pp. 639-645.
9. Bostwick DG (Pathology Editor), Stedman's Medical Dictionary, 26th.
Edition, Williams and Wilkens, Baltimore, MD (1995).
10. Bostwick DG. Atypical Adenomatous Hyperplasia of the Prostate. In:
Advances in Pathology and Laboratory Medicine, Eds. Weinstein RS, Graham
AR. Mosby-Year Book, Inc. Chicago, IL. (1996) pp. 191-207.
11. Bostwick DG. Is the Behavior of Prostate Cancer Understood? In: Questions
and Uncertainties about Prostate Cancer. Ed. Peeling WB. Blackwell Science,
Cambridge, MA 1996; pp 30-49.
12. Bostwick DG. Pathology of Benign Prostatic Hyperplasia. In: Textbook
of Benign Prostatic Hyperplasia. Eds. Kirby R, McConnell JD, Fitzpatrick
JM, Roehrborn CG, Boyle P. ISIS Medical Media, Oxford, UK 1996; pp 91-104.
13. Bostwick DG, Oesterling JE. The Urologic and Male Reproductive Systems.
In: Pathology for the Surgeon. Eds. Banks PM, Kraybill WG. W.B. Saunders
Company, Philadelphia, PA 1996; pp 217-233.
14. Bostwick DG. Pathology of Prostate Cancer. In: Urologic Cancer, Blackwell
Science, Cambridge, MA 1997, pp 15-47.
15. Bostwick DG, MacLennan GT. Prostate-Specific Antigen in Diagnostic
Pathology of Prostate Cancer. In: Urology Annual 1997. W.W. Norton &
Company. New York, NY.
16. Bostwick DG. Pathology of Prostate Cancer. In: International Handbook
of Prostate Cancer, Ed. David Kirk, Euromed Communications, United Kingdom,
1999, pp. 13-42.
17. Bostwick DG (Pathology Editor), Stedman's Medical Dictionary, 27th.
Edition, Williams and Wilkens, Baltimore, MD, 2000.
18. Bostwick DG. Prostatic Intraepithelial Neoplasia. In: Comprehensive
Textbook of Genitourinary Oncology, Second Edition, Eds. Vogelzang NJ,
Scardino PT, Shipley WS, Coffey DS. Lippincott Williams and Wilkins, Philadelphia,
PA (2000). pp. 604-611.
Abstracts and Letters
1. Bostwick
DG, Bose D, Srigley J, Grignon, Maksem J, and Young R. Morphologic Criteria
for Distinguishing Atypical Adenomatous Hyperplasia (Adenosis) from Well
Differentiated Adenocarcinoma of the Prostate. Lab Invest 1991 (Eightieth
Annual Meeting of the US and Canadian Academy of Pathology).
2. Bostwick D, Al-Annouf N, Choi C, Fazekas V, Jockle G, Gavel D, Vaughn
E, Bruce V. Establishment of the Formalin-Free Surgical Pathology Laboratory
Lab invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy
of Pathology).
3. Weaver MG, Abdul-Karin FW, Srigley J, Bostwick DG, Ro JY, and Ayala
AG. Paneth Cell-Like Changes of Prostate: A Histological, Immunohistochemical,
and Electron Microscopic Study. Lab Invest 1991 (Eightieth Annual Meeting
of the US and Canadian Academy of Pathology).
4. Doria M, Jin J, Wang H, Martinez R, Matthews J, and Bostwick D. Glycoconjugate
Expression in Hyperplastic, Dysplastic, and Malignant Prostatic Epithelium.
Lab Invest 1991 (Eightieth Annual Meeting of the US and Canadian Academy
of Pathology).
5. Bostwick DG, Jockle GA, and Fazekas VA. Patient - Initiated Laboratory
Testing. JAMA 1991; 265: 457.
6. Bostwick DG, Graham SD, Napalkov P, Abrahamsson P, di Sant'Agnese PA,
Algaba F, Hoisaeter PA, Lee F, Littrup P, Mostofi FK, Denis L, Schroeder
F, Murphy GP. Staging of Early Prostate Cancer: A Proposed Tumor Volume-Based
Prognostic Index. International Congress of the Internatonal Academy of
Pathology, October 1992 (abstract)
7. Bostwick DG, Srigley J, Grignon D, Maksem J, Humphrey P, van der Kwast
T, Bose D, Young R. Atypical Adenomatous Hyperplasia (AAH) of the Prostate.
International Congress of the International Academy of Pathology, October
1992
8. Bostwick DG, Amin MB, Dundore P, Marsh W, Schultz DS. Architectural
Patterns of High Grade Prostatic Intraepithelial Neoplasia. International
Congress of the International Academy of Pathology, October 1992
9. Devaraj LT, Bostwick DG. Atypical Basal Cell Hyperplasia of the Prostate:
Immunophenotypic Profile and Proposed Classification. International Congress
of the International Academy of Pathology, October 1992
10. Bostwick DG, Larson T. Microwave Transurethral Thermal Therapy: Pathologic
Findings in the Canine Prostate. Lab Invest 1993; 6:56A.
11. Bostwick DG, Cupp MR, Oesterling JE. Tumor Volume in Prostate Cancer:
Correlation of Needle Biopsy and Radical Prostatectomy. Lab Invest 1993;6:57A.
12. Bostwick DG, Dousa M, Crawford B. Neuroendocrine Differentiation in
Prostatic Intraepithelial Neoplasia (PIN). Lab Invest 1993; 6:57A.
13. Meneses MF, Bostwick DG, Kleer E, Kurtin PJ, Nascimento AG, Oesterling
JE. Leiomyosarcoma of the Prostate. Lab Invest 1993; 6:64A.
14. Amin MB, Bostwick DG. Kleer E, Kurtin PJ, Nascimento AG, Oesterling
JE. Leiomyosarcoma of the Prostate. Lab Invest 1993; 6:64A.
15. Amin MB, Osborne B, Discigel G, Bostwick DG. Malignant Lymphoma Involving
the Prostate: Report of 52 Cases. Lab Invest 1993; 6:54A.
16. Salomao D, Graham S, Bostwick DG. Vascular/Lymphatic Invasion in Prostate
Cancer Correlates with Patterns of Progression. Lab Invest 1993;6:54A.
17. Ellison E, Ferguson J, Zincke H, Bostwick DG. "Nucleolus-Poor"
Clear Cell Adenocarcinoma of the Prostate: A Distinctive Histologic Variant
in Patients Reciving Total Androgen Blockade. Lab Invest 1993; 6:59A.
18. de la Roza G, Dundore P, Bostwick DG. Intraepithelial Lymphocytes
in the Normal Human Prostate. Lab Invest 1993;6:58A.
19. Dudore P, Crawford B, Bostwick DG. Type 4 Collagenase Expression in
Prostatic Intraepithelial Neoplasia (PIN) and Adenocarcinoma. Lab Invest
1993; 6:58A.
20. Bostwick DG, Larson T. Microwave Transurethral Thermal Therapy: Pathological
Findings in the Canine Prostate. American Urological Association. San
Antonio, TX May 15-20, 1993.
21. Clinton SK, Bostwick DG, Moore BJ, Gugger ET, Williams AS, and Erdman
JW: Carotenoids are Found in the Human Prostate at Concentrations Which
Modulate Cellular Fucntion in vitro. FASEB, 1994.
22. Kletscher BA, Qian J, Bostwick DG, Andrews PE, and Zincke H: Prospective
analysis of multifocal renal cell carcinoma: influence of histologic pattern,
grade, stage, number, volume and DNA ploidy. (Abstract #994). 1994 Annual
Meeting of the AUA, May 14-19.
23. Ferguson JK, Bostwick DG, Suman, Zincke H, and OesterlingJE: PSA-detected
prostate cancers: pathological characteristics of ultrasound visible versus
ultrasound invisible tumors. (Abstract #1348) 1994 Annual Meeting of the
AUA.
24. Bluestein DL, Bostwick DG, Bergstralh E, and Oesterling JE: Eliminating
the need for bilateral pelvic lymphadenectomy in select patients with
prostate cancer (Abstract #37) 1994 Annual Meeting of the AUA.
25. Blackwell K, Bostwick DG, and Oesterling JE: Examination of prostate
specific antigen levels in prostate cancer patients using PSA-cancer density:
a new concept to improve PSA's preoperative prognostic value. (Abstract
#1202) 1994 Annual Meeting of the AUA.
26. Schneider BG, Pulitzer DR, Moehlmann RD, Prihoda TJ, Bostwick DG,
Saldivar V, Rodriguez-Martinez HA, Gutierrez-Diaz ME, O'Connell P. Microsatellite
Instability and Loss of Heterozygosity in Gastric Cancer (Abstract) 1994
American Society of Human Genetics.
27. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG. Immunophenotype
of Intraepithelial Neoplasia and Carcinoma of the Canine Prostate. Am
Assoc Cancer Res, 1994.
28. Bostwick DG. Early Prostate Cancer: A Pathologist's Perspective. Minnesota
Cancer Surveillance System (MCSS Notes) Sept. 1994, Vol. 8.
29. Larson T, Bostwick D, Corica A. Pathologic Comparison of Human Prostate
Between Treatment of Transurethral Laser Versus Transurethral Microwave
Thermal Therapy. 12th World Congress on Endourology and SWL 8th Annual
Frontiers in Endourology 10th Basic Research Symposium. St. Louis, MO
Dec. 2-6, 1994.
30. Larson TR, Corica A, Bostwick D. Extent of Thermal Cell Death Correlated
to Accurate Interstitial Temperatures of Ten Pathological Prostate Specimens
Using Urologix T3 Microwave Transurethral Thermal Therapy Unit. 23rd Congress
of Societe Internationale D'Urologie. Sydney, Australia Sept. 18-22, 1994.
31. Allam CK, Bostwick DG, Hayes JA, Upton MP, Wade GG, Domanowdki GF,
Klein MA, Boling EA, Stilmant MM. Interobserver Variability in the Diagnosis
of High Grade Prostatic Intraepithelial Neoplasia and Adenocarcinoma.
USCAP Annual Pathology Mtg, Mod Pathol 1995 , page 71A.
32. Bostwick DG, Qian J, Frankel K. The Diagnosis of High Grade Prostatic
Intraepithelial Neoplasia on Needle Biopsies. USCAP Annual Pathology Mtg,
Mod Pathol 1995, page 73A.
33. Cheville JC, Bostwick DG. Post-Atrophic Hyperplasia of the Prostate,
Histologic Features in 100 Whole-Mount Radical Prostatectomies. USCAP
Annual Pathology Mtg, Mod Pathol 1995, page 74A.
34. Dundore PA, Nascimento AG, Cheville JC, Bostwick DG. Carcinoma Sarcoma
of the Prostate. USCAP Annual Pathology Mtg, Mod Pathol 1995, page 75A.
35. Goldstein NS, Begin L, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal
or No Cancer in Radical Prostatectomy Specimens: Report of 13 Cases of
the "Vanishing Cancer Phenomenon." USCAP Annual Pathology Mtg,
Mod Pathol 1995 #434, page 76A.
36. Qian J, Jenkins RB, Takahashi S, Lieber MM, Bostwick DG. Detection
of Genetic Alterations in Prostatic Intraepithelial Neoplasia by Fluorescence
In Situ Hybridization. USCAP Annual Pathology Mtg, Mod Pathol 1995, page
81A.
37. Ferreiro JA, Myers JL, Bostwick DG. Accuracy of Frozen Section in
Diagnostic Surgical Pathology: One Year's Experience at the Mayo Clinic
with 24, 880 Cases. USCAP Annual Pathology Mtg, Mod Pathol 1995, page
157A.
38. Ferreiro JA, Grivold JJ, Bostwick DG. The Accuracy of Frozen Section
in Diagnosis of Mammographically Directed Breast Biopsies: Results of
1,490 Consecutive Cases. USCAP Annual Pathology Mtg, Mod Pathol 1995,
page 17A.
39. R. Schleicher R, Bandea C, Zhang M, Tan W, Bostwick D, Hunter S, Varma
V. Neurofilament mRNA is Down Regulated in Prostatic Adenocarcinoma. USCAP
Annual Pathology Mtg, Mod Pathol 1995, page 83A.
40. Bostwick DG, Larson T, Corica A. Pathological Comparison of Human
Prostate Between Treatment of Transurethral Laser Versus Transurethral
Microwave Thermal Therapy. 1996 AUA Annual Meeting J Urol 1996; 153:231A.
41. Harmon WJ, Barrett DM, Qian J, Bostwick DG, Gokcen M. Transurethral
Enzyme Ablation of the Prostate (TEAP): A Canine Model. 1996 AUA Annual
Meeting
J Urol 1996; 153:399A.
42. Kletscher BA, Qian J, Bostwick DG, Zincke H, Blute ML, Barrett DM.
Prospective Analysis on the Incidence of Ipsilateral Adrenal Metastasis
in Renal Cell Carcinoma. 1996 AUA Annual Meeting J Urol 1996; 153:547A.
43. Monda JM, Lauvetz RW, Qian J, Bostwick DG, Husmann DA. Myoperitoneal
Bladder Augmentations: The Incidence of Cancer and Bacterial Colonization
in the Rat Model. 1996 AUA Annual Meeting J Urol 1996; 153:476A.
44. Ferguson JK, Qian J, Husmann DA, Bostwick DG. Increased Androgen Receptor
Expression is Associated with Decreased Survival in Metastatic Prostate
Cancer. 1996 AUA Annual Meeting J Urol 1996; 153:483A.
45. Dundore PA, Blute ML, Farrow GM, Bostwick DG. Subclinical Biochemical
(PSA) Failure in Ninety Men 50 Years of Age and Younger with Prostate
Cancer Treated by Radical Retropubic Prostatectomy. 1996 AUA Annual Meeting
J Urol 1996; 153:505A.
46. Gould VE, Doljanskaia V, Gooch G, Bostwick DG. Molecular Stability
of the Glycoprotein A-80 in Prostatic Adenocarcinma Following Androgen
Deprivation Therapy. USCAP Annual Pathology Mtg Mod Pathol 1996; 9:73A.
47. Gould VE, Doljanskala G, Gooch G, Bostwick DG. Immunolocalization
of Glycoprotein A-80 in Prostatic Hyperplasia, Dysplasia, and Carcinoma.
Mod Pathol 1996; 9:73A.
48. Lopez-Beltran A, Pacelli A, Farrow GM, Bostwick DG. Carcinosarcoma
of the Urinary Bladder: Clinicopathologic Study of 41 Cases. USCAP Annual
Pathology Mtg Mod Pathol 1996; 9:77A.
49. Lopez-Beltran A, Pacelli A, Qian J, Jenkins RB, Bostwick DG. Atypical
Adenomatous Hyperplasia of the Prostate: Immunophenotype, Genotype, and
DNA Ploidy Analysis. USCAP Annual Pathology Mtg Mod Pathol 1996; 9:77A.
50. MacLennan GT, Farrow GM, de Matteis A, Bostwick DG. Renal Cell Carcinoma
of Collecting Duct Type: A Report of 16 Cases. USCAP Annual Pathology
Mtg Mod Pathol 1996; 9:77A.
51. Qian J, Bostwick DG, Jenkins RB. C-MYC Gene Amplification and Chromosomal
Anomalies in Prostatic Intraepithelial Neoplasia and Stage D1 Carcinoma
by Fluorescence In-Situ Hybridization. USCAP Annual Pathology Mtg Mod
Pathol 1996; 9:81A.
52. Qian J, Bostwick DG, Takahashi S, Borell TJ, Brown JA, Lieber MM,
Jenkins RB. Comparison of Fluorescence In Situ Hybridization Analysis
of Isolated Nuclei and Routine Histologic Sections of Prostatic Carcinoma.
USCAP Annual Pathology Mtg Mod Pathol 1996; 9:81A.
53. Bostwick DG. Prostate Cancer and Androgen Deprivation - Reply. CAP
Today August 1996, Vol. 10.
54. Waters DJ, Patronek GJ, Bostwick DG, Glickman LT. Comparing the Age
at Prostate Cancer Diagnosis in Humans and Dogs. J Natl Cancer Inst Nov
20 1996; 88:1686-7.
55. Waters DJ, Bostwick DG, Qian J, Hayden DW, Sweet D, Hendrick MJ, Klausner
JS, Bell FW. Skeletal Metastases in Dogs with Spontaneous Prostate Cancer.
(Submitted to Am Assoc Cancer Res Meeting 1997)
56. Bock BJ, Bostwick DG. Prostatic Peripheral Zone Adenocaricnoma Mimicking
Ductal Adenocarcinoma: Study of 17 Cases. Mod Pathol 1997; 10:70A.
57. Bostwick DG, MacLennan GT. Atypical Small Acinar Proliferation of
the Prostate Suspicious for Malignancy in Needle Biopsies: Histologic
Features and Clinical Significance in 33 Cases. Mod Pathol 1997; 10:70A.
58. Bostwick DG, Bostwick KC. No Residual Cancer in Radical Prostatectomy
Specimens: Incidence in 6843 Cases from 1966 to 1995. Mod Pathol 1997;
10:71A.
59. Cheng L, MacLennan GT, Bostwick DG, Jacobs GH, Abdul-Karim FW. Paneth
Cell Differentiation in the Benign Prostate. Mod Pathol 1997; 10:71A.
60. Cheville JC, Reznicek MJ, Bostwick DG. The Focus of Atypical Glands
Suspicious for Malignancy in Prostate Needle Biopsy Specimens: Evaluation
of Cases Seen in a Community Practice. Mod Pathol 1997; 10:71A.
61. Chuaqui RF, Englert CR, Strup SE, Vocke CD, Zhengping Z, Duray PH,
Bostwick DG, Linehan WM, Liotta LA, Emmert-Buck MR. Comparison of Gene
Expression in Microdissected Prostate Normal and Tumor Epithelium in a
Patient with Clinically Aggressive Cancer. Mod Pathol 1997; 10:72A.
62. Dundore PA, Bostwick DG. Agressiveness of Prostate Cancer in Men Age
50 and Under Treated by Radical Retropubic Prostatectomy. Comparison with
Older Men Using PSA Failure as An Endpoint. Mod Pathol 1997; 10:73A.
63. Egan AJM, Bostwick DG. Prediction of Extraprostatic Extension of Prostate
Cancer Based on Needle Biopsy Findings: Perineural Invasion Lacks Independent
Significance. Mod Pathol 1997; 10:74A.
64. Goldstein NS, Bostwick DG. Histologic Type and Grade of Renal Cell
Carcinoma: Clinical Significance in 813 Cases with Long-Term Follow-up.
Mod Pathol 1997; 10:76A.
65. MacLennan GT, Farrow GM, Bostwick DG. Immunohistochemistry in the
Evaluation of Renal Cell Carcinoma: A Critical Appraisal. Mod Pathol 1997;
10:81A.
66. Muir TE, Pacelli A, Farrow GM, Bostwick DG. Mesonephric Remnants of
the Prostate: Incidence and Clinical Significance. Mod Pathol 1997; 10:83A.
67. Orozco R, Schwob V, Bassler T, Egan A, O’Dowd G, Bostwick DG.
The Diagnosis of “Suspicious” for Adenocarcinoma in Prostate
Biopsies: Evaluation of Follow-up Biopsies. Mod Pathol 1997; 10:84A.
68. Pacelli A, Bostwick DG. Clinical Significance of Intestinal Metaplasia
of the Urinary Bladder. Mod Pathol 1997; 10:84A.
69. Pacelli A, Bostwick DG. The Clinical Significance of High-Grade Prostatic
Intraepithelial Neoplasia in Transurethral Resection Specimens. Mod Pathol
1997; 10:85A.
70. Pacelli A, Lopez-Beltran A, Egan AJM, Bostwick DG. Prostatic Adenocarcinoma
with Glomeruloid Features. Mod Pathol 1997; 10:85A.
71. Qian J, Bostwick DG, MacLennan GT, Brown J, Farrow GM, Jenkins RB.
Detection of Genetic Change in Collecting Duct Carcinoma of the Kidney
by Fluorescence In Situ Hybridization (FISH). Mod Pathol 1997; 10:85A.
72. Qian J, Jenkins RB, Bostwick DG. Is the Cribriform Pattern of Prostate
Cancer Undergraded? A Fluorescence In Situ Hybridization Study of Cribriform
Cancer and Cribriform PIN in 25 Whole Mount Prostates. Mod Pathol 1997;
10:86A.
73. Wang X, Farrow GM, Bostwick DG. Prostatic Stromal Hyperplasia with
Atypia: A Study of 10 Cases. Mod Pathol 1997; 10:94A.
74. Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber
K, Lieber MM, Liu W, Smith DI, Jenkins RB. A Molecular Cytogenic analysis
of 7q31 in Prostate Cancer. (AACR Annual Meeting, 1998).
Back to Dr. Bostwick's Educational & Professional Background